Company intelligence / Profile preview

AquiNovo

Ness Ziona, Central District, Israelaquinovo.com ↗

Ownership: Private
Development stage: Other

Overview

Lead product has demonstrated improved growth and feed utilization in farmed fish (tilapia), resulting in higher yields with less feed. Initial results also show higher fillet rate and better size distribution. Product launch was projected for 2023.

Therapeutic areas: Endocrinology
Modalities: PeptidesSynthetic bioactive peptides
Industry: Veterinary

Partnerships

Licensed core technology from Hebrew University of Jerusalem; no major pharma/biotech partnerships disclosed

Beyond the preview

Go deeper on AquiNovo.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on AquiNovo.

Explore the full profile